Another Trademark Setback for CBD Products
Friends,
The Trademark Trial and Appeal Board (the “TTAB”) affirmed this month a decision by the United States Patent Trademark Office (“USPTO”) denying cannabis brands, specifically products containing CBD, from getting trademark protection for dietary supplements.
The case began with a March 18, 2015, trademark filing for “CW” by the Colorado-based cannabis company Stanley Brother Social Enterprises, LLC as a dietary supplement. The examiner at the USPTO rejected the filing because Stanley Brothers was selling dietary supplements containing CBD under the brand CW, which is expressly not allowed by the Food and Drug Administration (“FDA”).
Since 2018, when the Food and Drug Administration approved Epidiolex, a drug with CBD as an active ingredient for treatment of two epilepsy disorders, the FDA has considered CBD to be a drug and therefore cannot be considered a dietary supplement. It was the FDA’s designation of CBD as a drug and not a dietary supplement that the TTAB relied upon in denying the CW trademark to the Stanley Brothers. The TTAB stated that there is no legal basis for the Stanley Brothers to obtain a trademark for CBD-based dietary supplements since “there is no evidence of record that CBD was marketed in food before the substantial clinical investigations of CBD.”
While this opinion was not necessarily a surprise given how the USPTO has been handling cannabis applications, it does highlight the difficulties cannabis businesses, even federally legal ones, can face when trying to expand and grow their brand. McAllister Garfield routinely assists clients in and out of cannabis in determining the correct trademark strategy for their brands, including providing solutions for federal filings for dietary supplements in other classes. If you have any questions or need help
navigating a cannabis trademark application, please contact us.
Sincerely,
Dan Kramer
Related Article
Emerging Trends In Psychedelic Laws: Implications for Practitioners
As the psychedelic renaissance continues, legal landscapes globally are evolving rapidly. What was once a fringe area of medical research and therapy is now moving towards mainstream acceptance, driven by promising results in clinical trials and changing public perceptions. For practitioners, these shifts present both exciting opportunities and complex challenges. This blog post explores emerging […]
McAllister Law Office – Psychedelic Law Update – June 2024
1. With Sean McAllister as one of their lawyers, The Church of The Eagle and The Condor is recognized as the third religious organization authorized to use ayahuasca in the United States. In a career highlight, I was honored to one of five lawyers representing The Church of The Eagle and The Condor (“CEC”) in […]
Navigating New Realms: The Crucial Role Of Legal Guidance In Psychedelic Business Start-Ups
In recent years, the interest in psychedelics for therapeutic purposes has surged, offering a promising frontier in both medical science and entrepreneurship. However, the burgeoning field of psychedelic businesses also presents a unique set of legal challenges. For start-ups in this industry, navigating the complex regulatory environment is not just about compliance, but also about […]